Although gliomas are rare diseases, they represent a societal problem for several reasons. The most common and at the same time the most aggressive glioma is glioblastoma, an infiltratively growing tumor with early recurrences despite combined trimodality standard treatment including surgery, radiation and systemic therapy. Medians of overall survival are between 14-16 months even for patients treated in this way, which makes glioblastoma one of the most difficult to treat oncological diseases ever.

The integrated diagnosis of diffuse gliomas should be performed according to a standardized algorithm:

Testing of molecular biomarkers for the diagnosis of diffuse gliomas . This KDP addresses the diagnosis, monitoring and treatment of all types of glioma in adults and addresses the following clinical questions: What is the most effective strategy for using imaging methods in newly diagnosed glioma? What is the most effective strategy for using molecular biomarker testing in newly diagnosed glioma? What is the most effective method to optimize the performance of maximally safe glioma resection (e.g. using 5-ALA, awake craniotomy, intraoperative ultrasound, intraoperative MR)? What is the optimal timing and optimal extent of resection for suspected low-grade glioma? What is the optimal postoperative treatment (monitoring, surgery, radiotherapy, chemotherapy, or combined treatment) in histologically verified low grade glioma? What is the optimal course of treatment after surgery (radiotherapy, chemotherapy, a combination thereof, or other therapies such as metformin or tumor-treating fields) for newly diagnosed high grade glioma? What is the optimal treatment (surgery, radiotherapy, chemotherapy, their combination, or other procedures such as metformin or tumor-treating fields) for recurrent high-grade glioma? What is the most effective follow-up protocol (including duration, frequency and tests) to detect recurrence after treatment of gliomas?